Skip to content
Inciteful Med

The Biology, Genetics, and Subtypes of Sickle Cell Disease

Last updated:

Sickle cell disease is caused by a genetic mutation in the HBB gene that makes red blood cells stiff and sickle-shaped. Your specific subtype, such as HbSS or HbSC, depends on the genes inherited from your parents and determines the severity of symptoms and your long-term health risks.

Key Takeaways

  • • Sickle cell disease is caused by a single mutation in the HBB gene that alters how hemoglobin functions.
  • • The disease forces red blood cells into a rigid, sickle shape that blocks blood vessels and causes pain and organ damage.
  • • Your specific subtype, such as HbSS or HbSC, dictates the severity of your condition and your unique health risks.
  • • Fetal hemoglobin (HbF) helps protect red blood cells from sickling, and higher levels are linked to milder symptoms.
  • • Newborn screening can identify your exact subtype early, allowing doctors to begin life-saving preventative care immediately.

Sickle cell disease is not a single condition, but a group of inherited blood disorders that change how your body produces hemoglobin—the protein in red blood cells that carries oxygen to your organs and tissues [1]. While it is often discussed as one disease, the biology and genetics behind it are complex. Understanding your specific subtype is the first step in managing your health, as different genetic variations can lead to very different symptoms and long-term outcomes [2][3].

The Genetic “Glitch”

The root of sickle cell disease is a single tiny change in the HBB gene, which provides instructions for making part of the hemoglobin protein [1]. In this mutation, an amino acid called glutamic acid (which loves water) is replaced by valine (which avoids water) [4][5].

This simple swap causes a major physical change:

  • Polymerization: When oxygen levels are low, this abnormal hemoglobin (called Hemoglobin S or HbS) sticks together in long, rigid rods [6][7].
  • Sickling: These rods push against the inside of the red blood cell, forcing it into a stiff, curved “sickle” shape [6].
  • Vaso-occlusion: Unlike round, flexible healthy cells, these stiff sickle cells get stuck in small blood vessels, blocking blood flow and causing pain and organ damage [6][8].

Common Subtypes of Sickle Cell Disease

Your subtype depends on which two hemoglobin genes you inherited—one from each parent.

Genotype Common Name Description Typical Severity
HbSS Sickle Cell Anemia Inheriting two “S” genes. This is the most common form [9]. Severe [10]
HbSC HbSC Disease Inheriting one “S” gene and one “C” gene (another abnormal type) [9]. Moderate [11]
HbSβ0\beta^{0} Sickle Beta-Zero Thalassemia Inheriting one “S” gene and one beta-thalassemia gene that produces no normal hemoglobin [3]. Severe [2]
HbSβ+\beta^{+} Sickle Beta-Plus Thalassemia Inheriting one “S” gene and one beta-thalassemia gene that still produces some normal hemoglobin [3]. Milder [12]

Severe vs. Milder Types

While every person’s experience is unique, HbSS and HbSβ0\beta^{0} are generally considered the most severe forms, often leading to earlier symptoms and a higher risk of stroke [10][13]. HbSC is often described as “milder” because patients typically have higher blood counts, but it carries a much higher risk for specific issues like retinopathy (damage to the back of the eye) [14][15].

Sickle Cell Trait (HbAS) vs. Disease

It is essential to distinguish between the “disease” and the “trait.”

  • Sickle Cell Trait (HbAS): This occurs when you inherit one “S” gene and one normal “A” gene [16]. People with the trait are generally healthy and do not have the disease [17]. In the U.S., about 1 in 13 Black or African American babies is born with the trait, while about 1 in 365 is born with the disease [18][19].
  • The Protective Edge: Historically, the trait became common in certain parts of the world because it provides natural protection against severe malaria [18][20].

The Role of Fetal Hemoglobin (HbF)

Before we are born, our bodies make fetal hemoglobin (HbF). Shortly after birth, the body switches to making “adult” hemoglobin [21].
HbF is special because it does not sickle. In fact, it acts like a “shield,” physically blocking the HbS from sticking together and forming those rigid rods [22][23].

Patients who naturally maintain higher levels of HbF often have much milder symptoms, fewer pain crises, and a lower risk of lung complications [24][25]. Many modern treatments work specifically by “turning back on” the production of this protective fetal hemoglobin [24][23].

Why Subtype and Screening Matter

Since 2006, all 50 U.S. states have performed newborn screening for sickle cell disease [26][27]. This blood test identifies the exact subtype within days of birth, which is life-saving [28][29].

Note: If you are an adult reading this, it is entirely possible you were diagnosed later in life if you were born before 2006, immigrated from a country without universal screening, or had a milder variant that went unnoticed.

Knowing the subtype allows doctors to:

  1. Predict Risks: For example, knowing an HbSS patient needs earlier brain scans to prevent stroke [30].
  2. Start Prevention: Beginning daily penicillin early to prevent life-threatening infections [31].
  3. Tailor Treatment: Choosing the right time to start disease-modifying therapies like Hydroxyurea [29].

While medical advancements have significantly improved survival—with 95% of children now reaching adulthood—the disease still impacts life expectancy, which is why early diagnosis and subtype-specific care are so critical [32][27].

Frequently Asked Questions

What causes sickle cell disease?
Sickle cell disease is caused by a genetic mutation in the HBB gene. This mutation produces abnormal hemoglobin, which causes red blood cells to stick together and become stiff, sticky, and sickle-shaped when oxygen levels are low.
What is the difference between sickle cell trait and sickle cell disease?
People with sickle cell trait inherit one abnormal hemoglobin gene and one normal gene, meaning they are generally healthy and do not have the disease. You must inherit two abnormal genes, one from each parent, to actually have sickle cell disease.
Which sickle cell subtype is the most severe?
Subtypes HbSS, also known as sickle cell anemia, and sickle beta-zero thalassemia are generally considered the most severe forms of the disease. They often lead to earlier symptoms and carry a higher risk for serious complications like stroke.
Why is fetal hemoglobin important in sickle cell disease?
Fetal hemoglobin acts like a natural shield that prevents abnormal hemoglobin from clumping together and sickling. Patients who naturally maintain higher levels of fetal hemoglobin typically experience milder symptoms and fewer pain crises.
How do doctors find out my exact sickle cell genotype?
Doctors determine your exact subtype using a blood test that analyzes the types of hemoglobin in your body. In the United States, this is typically done through a standard newborn screening test performed shortly after birth.

Questions for Your Doctor

  • • What is my (or my child’s) exact genotype? Is it HbSS, HbSC, or another subtype?
  • • How does my specific subtype affect the long-term risks I should be watching for?
  • • What is my fetal hemoglobin (HbF) level, and is it high enough to provide some natural protection?
  • • Are there specific genetic modifiers in my HBB gene that might make my symptoms milder or more severe?
  • • Based on my subtype, what is the best schedule for preventative screenings like eye exams or brain scans?

Questions for You

  • • Do I know my sickle cell status (disease vs. trait) and the status of my partner?
  • • How did I find out about my diagnosis? Was it through a newborn screening or later in life because of symptoms?
  • • Have I ever had a blood test that showed my hemoglobin levels or the specific types of hemoglobin I carry?
  • • What major symptoms, if any, have I experienced, and do they align with what is typical for my subtype?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Therapeutic promise of CRISPR-Cas9 gene editing in sickle cell disease and β-thalassemia: A current review.

    Almasoudi HH

    Current research in translational medicine 2025; (73(3)):103513 doi:10.1016/j.retram.2025.103513.

    PMID: 40252393
  2. 2

    Elevated tricuspid regurgitation velocity in congenital hemolytic anemias: Prevalence and laboratory correlates.

    Yates AM, Joshi VM, Aygun B, et al.

    Pediatric blood & cancer 2019; (66(7)):e27717 doi:10.1002/pbc.27717.

    PMID: 30907497
  3. 3

    Empirically Derived Profiles of Health-Related Quality of Life in Youth and Young Adults with Sickle Cell Disease.

    Keenan ME, Loew M, Berlin KS, et al.

    Journal of pediatric psychology 2021; (46(3)):293-303 doi:10.1093/jpepsy/jsaa104.

    PMID: 33249456
  4. 4

    Detection of hemoglobin variant HbS on the basis of discrepant HbA1c values in different measurement methods.

    Takeda Y, Kawanami D, Utsunomiya K

    Diabetology international 2016; (7(2)):199-203 doi:10.1007/s13340-015-0237-8.

    PMID: 30603264
  5. 5

    De novo rates of a Trypanosoma-resistant mutation in two human populations.

    Melamed D, Shemer R, Bolotin E, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2025; (122(35)):e2424538122 doi:10.1073/pnas.2424538122.

    PMID: 40854136
  6. 6

    Recommendations for the use of red blood cell exchange in sickle cell disease.

    Fort R

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2019; (58(2)):128-131 doi:10.1016/j.transci.2019.03.004.

    PMID: 30879904
  7. 7

    Cardiovascular consequences of sickle cell disease.

    Palomarez A, Jha M, Medina Romero X, Horton RE

    Biophysics reviews 2022; (3(3)):031302 doi:10.1063/5.0094650.

    PMID: 38505276
  8. 8

    [Disease genotype, haplotypes, diagnosis and associated studies in sickle cell anemia].

    Díaz-Matallana M, Márquez-Benítez Y, Martínez-Lozano JC, et al.

    Revista medica de Chile 2021; (149(9)):1322-1329 doi:10.4067/S0034-98872021000901322.

    PMID: 35319686
  9. 9

    Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond.

    Egesa WI, Nakalema G, Waibi WM, et al.

    International journal of pediatrics 2022; (2022()):3885979 doi:10.1155/2022/3885979.

    PMID: 36254264
  10. 10

    Sickle Cell Disease in Jordan: The Experience of a Major Referral Center.

    Oudat RI, Abualruz HS, Al-Shiek NKA, et al.

    Medical archives (Sarajevo, Bosnia and Herzegovina) 2021; (75(1)):27-30 doi:10.5455/medarh.2021.75.27-30.

    PMID: 34012195
  11. 11

    Sickle cell disease: A distinction of two most frequent genotypes (HbSS and HbSC).

    da Guarda CC, Yahouédéhou SCMA, Santiago RP, et al.

    PloS one 2020; (15(1)):e0228399 doi:10.1371/journal.pone.0228399.

    PMID: 31995624
  12. 12

    Serum Immunoglobulin Levels in Children with Sickle Cell Disease: A Large Prospective Study.

    Cherif-Alami S, Hau I, Arnaud C, et al.

    Journal of clinical medicine 2019; (8(10)) doi:10.3390/jcm8101688.

    PMID: 31618899
  13. 13

    The Epidemiology of Neurological Complications in Adults With Sickle Cell Disease: A Retrospective Cohort Study.

    Maduakor C, Alakbarzade V, Sammaraiee Y, et al.

    Frontiers in neurology 2021; (12()):744118 doi:10.3389/fneur.2021.744118.

    PMID: 34975711
  14. 14

    Natural history and rate of progression of retinopathy in adult patients with sickle cell disease: an 11-year follow-up study.

    Brandsen RP, Diederen RMH, Bakhlakh S, et al.

    Blood advances 2023; (7(13)):3080-3086 doi:10.1182/bloodadvances.2022009147.

    PMID: 36897257
  15. 15

    A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyurea.

    Setayesh T, Chi M, Oestreicher Z, et al.

    Blood 2025; (146(1)):13-28 doi:10.1182/blood.2024028136.

    PMID: 40324066
  16. 16

    MicroRNAs miR-451a and Let-7i-5p Profiles in Circulating Exosomes Vary among Individuals with Different Sickle Hemoglobin Genotypes and Malaria.

    Oxendine Harp K, Bashi A, Botchway F, et al.

    Journal of clinical medicine 2022; (11(3)) doi:10.3390/jcm11030500.

    PMID: 35159951
  17. 17

    Hemoglobin Genotypes Modulate Inflammatory Response to Plasmodium Infection.

    Harp KO, Botchway F, Dei-Adomakoh Y, et al.

    Frontiers in immunology 2020; (11()):593546 doi:10.3389/fimmu.2020.593546.

    PMID: 33424841
  18. 18

    Progressive glomerular and tubular damage in sickle cell trait and sickle cell anemia mouse models.

    Saraf SL, Sysol JR, Susma A, et al.

    Translational research : the journal of laboratory and clinical medicine 2018; (197()):1-11 doi:10.1016/j.trsl.2018.01.007.

    PMID: 29476712
  19. 19

    Acute care utilization in pediatric sickle cell disease and sickle cell trait in the USA: prevalence, temporal trends, and cost.

    Peterson EE, Salemi JL, Dongarwar D, Salihu HM

    European journal of pediatrics 2020; (179(11)):1701-1710 doi:10.1007/s00431-020-03656-x.

    PMID: 32394268
  20. 20

    Encephalitis Unraveled: The Unlikely Encounter of Sickle Cell Disease and Cerebral Malaria in a Teenager.

    Ruff C, Zerweck L, Bevot A, et al.

    Diagnostics (Basel, Switzerland) 2025; (15(12)) doi:10.3390/diagnostics15121470.

    PMID: 40564791
  21. 21

    Keap1-Nrf2 Heterodimer: A Therapeutic Target to Ameliorate Sickle Cell Disease.

    Chauhan W, Zennadi R

    Antioxidants (Basel, Switzerland) 2023; (12(3)) doi:10.3390/antiox12030740.

    PMID: 36978988
  22. 22

    Targeting fetal hemoglobin expression to treat β hemoglobinopathies.

    Steinberg MH

    Expert opinion on therapeutic targets 2022; (26(4)):347-359 doi:10.1080/14728222.2022.2066519.

    PMID: 35418266
  23. 23

    Synergistic Potential of Thalidomide and Hydroxyurea in Sickle Cell Disease Management: A Promising Combination Therapy.

    Samal P, Samal A, Lenka D, Bishoyi AK

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2026; (42(2)):370-377 doi:10.1007/s12288-025-02208-3.

    PMID: 41728140
  24. 24

    Chronic Hydroxyurea Therapy in Children with Sickle Cell Anemia: Mechanisms of Action, Systemic Effects, and Long-Term Safety.

    Fogliazza F, Berzieri M, Carbone G, et al.

    Journal of clinical medicine 2025; (14(23)) doi:10.3390/jcm14238599.

    PMID: 41375902
  25. 25

    Fetal hemoglobin modulates neurocognitive performance in sickle cell anemia✰,✰✰.

    Heitzer AM, Longoria J, Rampersaud E, et al.

    Current research in translational medicine 2022; (70(3)):103335 doi:10.1016/j.retram.2022.103335.

    PMID: 35303690
  26. 26

    Newborn Screening for SCD in the USA and Canada.

    El-Haj N, Hoppe CC

    International journal of neonatal screening 2018; (4(4)):36 doi:10.3390/ijns4040036.

    PMID: 33072956
  27. 27

    Newborn Screening for Hemoglobinopathies and Thalassemias: Brief History, Recent Activities, and Global Status-2026.

    Therrell BL

    International journal of neonatal screening 2026; (12(1)) doi:10.3390/ijns12010008.

    PMID: 41718422
  28. 28

    Paper-Based Diagnostics: Rethinking Conventional Sickle Cell Screening to Improve Access to High-Quality Health Care in Resource-Limited Settings.

    Piety NZ, Shevkoplyas SS

    IEEE pulse 2017; (8(3)):42-46 doi:10.1109/MPUL.2017.2678658.

    PMID: 28534763
  29. 29

    Fostering a healthier generation of children with sickle cell disease through advancements in care.

    Franco E, Nimura C, McGann PT

    Pediatric research 2025; (97(4)):1280-1289 doi:10.1038/s41390-024-03566-w.

    PMID: 39271903
  30. 30

    American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.

    DeBaun MR, Jordan LC, King AA, et al.

    Blood advances 2020; (4(8)):1554-1588 doi:10.1182/bloodadvances.2019001142.

    PMID: 32298430
  31. 31

    Newborn Screening for Sickle Cell Disease Using Point-of-Care Testing in Low-Income Setting.

    Alvarez OA, Hustace T, Voltaire M, et al.

    Pediatrics 2019; (144(4)) doi:10.1542/peds.2018-4105.

    PMID: 31530717
  32. 32

    CDC Grand Rounds: Improving the Lives of Persons with Sickle Cell Disease.

    Hulihan M, Hassell KL, Raphael JL, et al.

    MMWR. Morbidity and mortality weekly report 2017; (66(46)):1269-1271 doi:10.15585/mmwr.mm6646a2.

    PMID: 29166365

This page explains the biology and genetics of sickle cell disease for educational purposes only. Always consult your hematologist or primary care doctor to discuss your specific genotype and individual care plan.

Stay up to date

Get notified when new research about Sickle cell anemia is published.

No spam. Unsubscribe anytime.